Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study

OBJECTIVES: We assessed the safety, tolerability, pharmacokinetics, preliminary antitumour activity and pharmacodynamics of danvatirsen, an antisense oligonucleotide targeting signal transducer and activator of transcription 3 (STAT3), monotherapy and danvatirsen plus durvalumab, an antiprogrammed c...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishina, Tomohiro, Fujita, Tomoko, Yoshizuka, Naoto, Sugibayashi, Ko, Murayama, Kosho, Kuboki, Yasutoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594513/
https://www.ncbi.nlm.nih.gov/pubmed/36270753
http://dx.doi.org/10.1136/bmjopen-2021-055718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594513/
https://www.ncbi.nlm.nih.gov/pubmed/36270753
http://dx.doi.org/10.1136/bmjopen-2021-055718

Ejemplares similares